United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cytarabine - solution for injection - 100mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cytarabine - solution for injection - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cytarabine - solution for injection - 20mg/1ml

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz), daunorubicin (unii: zs7284e0zp) (daunorubicin - unii:zs7284e0zp) - cytarabine 100 mg in 20 ml - vyxeos is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older. the use of vyxeos is contraindicated in patients with the following: risk summary based on anecdotal data of cytarabine in pregnant women and results of studies of daunorubicin and cytarabine in animals, vyxeos can cause embryo-fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of vyxeos, daunorubicin, or cytarabine in pregnant women. daunorubicin and cytarabine are reproductive and developmental toxicants in multiple species (mice, rats, and/or dogs), starting at a dose that was approximately 0.02 times the exposure in patients at the recommended human dose on a mg/m2 basis [see animal data] . patients should be advised to avoid becoming pregnant while taking vyxeos. if this drug is used during pregnancy, or if the patient becomes pregnant while taking th

Canada - English - Health Canada

pfizer canada ulc - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - cytarabine may be used alone or in combination with other chemotherapeutic agents. it is indicated for induction of remission of leukaemia, particularly for acute myeloid leukaemia, in adults and children. cytarabine has been used for remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in the treatment and maintenance therapy of meningeal leukaemia and other meningeal neoplasms.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - cytarabine may be used alone or in combination with other chemotherapeutic agents. it is indicated for induction of remission of leukaemia, particularly for acute myeloid leukaemia, in adults and children. cytarabine has been used for remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in the treatment and maintenance therapy of meningeal leukaemia and other meningeal neoplasms.

Canada - English - Health Canada

sterimax inc - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

mylan institutional llc - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.